GKIM
REGN icon

GW&K Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

GW&K Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82K Buy
131
+11
+9% +$7.49K ﹤0.01% 505
2026
Q1 		$93K Buy
120
+1
+0.8% +$766 ﹤0.01% 465
2025
Q4 		$92K Buy
119
+4
+3% +$2.72K ﹤0.01% 464
2025
Q3 		$65K Buy
115
+34
+42% +$19.2K ﹤0.01% 495
2025
Q2 		$43K Sell
81
-10
-11% -$5.58K ﹤0.01% 539
2025
Q1 		$58K Buy
91
+4
+5% +$2.75K ﹤0.01% 469
2024
Q4 		$62K Hold
87
– – ﹤0.01% 446
2024
Q3 		$91K Buy
87
+8
+10% +$8.9K ﹤0.01% 403
2024
Q2 		$83K Buy
79
+6
+8% +$5.82K ﹤0.01% 399
2024
Q1 		$70K Buy
73
+14
+24% +$13.3K ﹤0.01% 396
2023
Q4 		$52K Buy
59
+1
+2% +$823 ﹤0.01% 401
2023
Q3 		$48K Buy
58
+25
+76% +$19.6K ﹤0.01% 396
2023
Q2 		$24K Buy
+33
New +$25.4K ﹤0.01% 455
2022
Q3 		– Sell
-19
Closed -$11K – 738
2022
Q2 		$11K Buy
19
+10
+111% +$6.5K ﹤0.01% 467
2022
Q1 		$6K Buy
+9
New +$5.69K ﹤0.01% 522

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GW&K Investment Management's REGN Position: Q2 2026 in Review

GW&K Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 9.2% in Q2 2026, buying an estimated $7.49K and bringing the position to 131 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #505.

GW&K Investment Management first reported a position in REGN in Q1 2022 and has held it in 15 quarters since. The position peaked at $93K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • GW&K Investment Management held 131 shares of Regeneron Pharmaceuticals worth $82K as of Q2 2026.
  • GW&K Investment Management bought 11 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.49K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of GW&K Investment Management's portfolio in Q2 2026, its #505 holding.
  • GW&K Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • GW&K Investment Management's Regeneron Pharmaceuticals position peaked at $93K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.